Category Archives: Emerging Markets

Ad Agency Encourages Pharma Marketers to Reboot

By Ben Comer | Published: April 16, 2013
People tell you who they are, but we ignore it – because we want them to be who we want them to be. – Don Draper At the beginning of the Reboot Camp – held at New York City’s Alexandria Center on April 12 – Intouch Solutions’ CEO Faruk Capan declared the days of Don Draper [...]
Also posted in Advertising, Agency Insight, FDA, Marketing, Patient Communication, People, Regulatory, Sales, Strategy, Technology, healthcare, leadership, patient education, social media | Tagged , , , , , , , , , , , , | 1 Comment

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

By William Looney | Published: April 3, 2013
Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Also posted in Global, IP, Legal, Manufacturing, Market Access, Strategy, pricing | Tagged , , , , , , , , | 6 Comments

Going Global: The New Pharma Workforce

By Guest Blogger | Published: March 7, 2013
Mexico and other emerging markets top the skills gap list By Susan Crowley Finding the right people for the right job might seem an afterthought for big Pharma companies that have cut their US workforce by more than 250,000 in the past 10 years.  But the rush is back on for talent:  the challenge is [...]
Also posted in Global, Guest Blog | Tagged , , , | 1 Comment

Emerging Countries' R&D: A Contest, but No Wipe Out

By Clark Herman | Published: March 5, 2013
Emerging country markets are widely viewed as Big Pharma’s ace in the hole to replace declining rates of innovation in the US and Europe, with numerous studies claiming the BRICK nations (the ‘K’ is from South Korea) are at the center of a revolutionary global shift in the source points for new ideas —  what [...]
Also posted in Global, IP, R&D | Tagged , , , | 2 Comments

Trends in R&D: The Widening Gap between Success and Failure

By Clark Herman | Published: January 31, 2013
The Office of Health Economics (OHE) has released a new study examining drug development costs over the past 30 years. The study finds that out-of-pocket costs to bring a new medicine to market have increased over this period by 600%, success rates from proof of concept to registration have decreased at least twofold since the [...]
Also posted in Europe, R&D, Strategy, Technology | Tagged | 1 Comment